RTP Mobile Logo
Recent Advances in Medical Oncology: Urothelial Bladder Carcinoma (Faculty Presentations)
Released October 2020

Featuring slide presentations and related discussion from Dr Arjun Balar, Prof Thomas Powles and Dr Arlene Siefker-Radtke. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of bladder cancer.

    OVERVIEW OF ACTIVITY
    An estimated 81,400 new cases of bladder cancer will be diagnosed in 2020, and 17,980 deaths will be attributable to this disease. Optimal treatment of the most common form, urothelial bladder carcinoma (UBC), depends on the stage and grade of the tumor and patient comorbidities. For those patients who present with or develop metastatic lesions beyond the bladder, cure is not attainable and the goal of therapy is to prolong quantity and quality of life. Historically, therapeutic options for metastatic UBC were largely limited to chemotherapy, but more recently a number of novel agents and strategies have yielded favorable outcomes, leading to a spate of FDA approvals and the promise of more. In addition, significant enthusiasm exists for the further investigation of these approaches in earlier, nonmetastatic settings. These developments, coupled with the plethora of controversies and uncertainties plaguing the current management of UBC, provide the impetus for continuing education for practicing clinicians.

    These presentations recorded in advance of and in conjunction with a live CME webinar originally planned as a satellite symposium for the 2020 ASCO Annual Meeting in partnership with the University of South Florida (USF Health) Office of Continuing Professional Development, uses the perspectives of leading clinical investigators to address some of the most frequently encountered questions and controversies in the management of UBC. By providing information on the latest research developments and their potential application in practice, this activity is designed to assist medical oncologists, hematology-oncology fellows and other allied healthcare providers with the formulation of up-to-date clinical management strategies.

    LEARNING OBJECTIVES

    • Compare and contrast the available clinical trial evidence with the use of immune checkpoint inhibitors for the treatment of urothelial bladder carcinoma (UBC) to determine the current utility of these agents in clinical practice.
    • Consider the recent FDA approval of pembrolizumab for high-risk, non-muscle-invasive UBC that is unresponsive to bacillus Calmette-Guérin, and determine how this agent can be appropriately integrated into current care.
    • Evaluate available data and ongoing trials investigating the use of anti-PD-1/PD-L1 antibodies as neoadjuvant or adjuvant therapy for muscle-invasive bladder cancer, and refer eligible patients for appropriate study participation.
    • Review available clinical trial data leading to the recent FDA approval of the anti-PD-L1 antibody avelumab as maintenance therapy following response to first-line platinum-based chemotherapy for patients with metastatic UBC, and incorporate this novel treatment strategy into current management algorithms.
    • Assess available and emerging clinical trial data evaluating the use of anti-PD-1/PD-L1 antibodies in combination with chemotherapy for patients with previously untreated metastatic UBC, and consider the potential role of this approach in routine practice.
    • Recognize the FDA approval of erdafitinib for patients with advanced UBC and susceptible FGFR3 or FGFR2 genetic alterations whose disease has progressed during or after at least 1 line of platinum-containing chemotherapy, and determine how this agent may be appropriately integrated into clinical practice.
    • Recall the mechanism of action and pivotal clinical trial findings with enfortumab vedotin for previously treated locally advanced or metastatic UBC, and identify patients for whom treatment with this novel compound would be appropriate.
    • Appraise available research data and ongoing clinical trials evaluating anti-PD-1/PD-L1 antibodies in combination with targeted agents or other immunotherapeutic strategies for metastatic UBC, and counsel appropriately selected patients about participation in active research protocols.

    COMPETENCIES TO BE ADDRESSED
    Patient Care and Procedural Skills and Medical Knowledge

    CONTACT INFORMATION
    If you have questions regarding credit, please contact cpdsupport@usf.edu.

    ACCREDITATION STATEMENT
    USF Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    USF Health designates this enduring material for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 2.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

    For ABIM MOC points, your information will be shared with the ABIM through USF Health's ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for MOC points to appear on your ABIM records.

    Personal information and data sharing: Research To Practice and USF Health aggregate deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of a video component. To receive CME credit and ABIM MOC points, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ASCOBladder20/Presentations/CME.

    CONTENT VALIDATION AND DISCLOSURES
    USF Health adheres to ACCME Standards regarding commercial support of continuing medical education. It is the policy of USF Health and Research To Practice that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved and also that speakers will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Arjun Balar, MD
    Associate Professor, Department of Medicine
    Director, Genitourinary Medical Oncology Program
    NYU Perlmutter Cancer Center
    New York, New York

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Janssen Biotech Inc, Merck, Nektar, Pfizer Inc, Seattle Genetics; Contracted Research: AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Immunomedics Inc, Janssen Biotech Inc, Merck, Nektar, Pfizer Inc, Seattle Genetics.

    Thomas Powles, MBBS, MRCP, MD
    Professor of Genitourinary Oncology
    Barts Cancer Institute
    Director of Barts Cancer Centre
    Queen Mary University of London
    London, United Kingdom

    Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eisai Inc, Exelixis Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Merck Serono, Merck Sharp & Dohme Corp, Novartis, Pfizer Inc, Roche Laboratories Inc, Seattle Genetics; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eisai Inc, Exelixis Inc, Ipsen Biopharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Merck Serono, Merck Sharp & Dohme Corp, Novartis, Pfizer Inc, Roche Laboratories Inc, Seattle Genetics.

    Arlene Siefker-Radtke, MD
    Professor
    Department of Genitourinary Medical Oncology
    Division of Cancer Medicine
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Bavarian Nordic, Genentech, a member of the Roche Group, Janssen Biotech Inc, Merck, Mirati Therapeutics, Nektar, Pfizer Inc, Seattle Genetics; Contracted Research: Janssen Biotech Inc; Speakers Bureau: Janssen Biotech Inc.

    COURSE DIRECTOR/PANEL MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

    USF HEALTH CPD STAFF AND RESEARCH TO PRACTICE CME PLANNING COMMITTEE — Members, Staff, and Reviewers have no relevant conflicts to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Astellas and Seattle Genetics, AstraZeneca Pharmaceuticals LP, and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.

    Release date: October 2020
    Expiration date: October 2021

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):